Macro monthly | Market commentary Incentives and constraints for Trump and Xi in trade negotiations

Are the incentives of Presidents Trump and Xi aligned to avoid a damaging trade war?

06 Aug 2018


  • Tensions between the US and China are likely to rise in coming months
  • Expect market volatility to pick up as the Trump administration presses ahead with tariffs
  • Investors should not underestimate growth stabilization outside of the US, including the effects of China’s monetary and fiscal stimulus
  • Remain constructive on global equities, with a keen focus on whether trade disruptions are meaningfully affecting business investment and hiring decisions
  • Hedges for further trade escalation include US duration and short the Chinese yuan and Korean won versus the safe haven Japanese yen

Incentives and constraints for Trump and Xi

Back in March, we wrote that while a miscalculated step in trade negotiations was a risk to economy and markets, Presidents Trump and Xi are sufficiently aligned to avoid a damaging trade war. However, the stakes now have surely risen.

President Trump is incentivized to continue pushing China on trade over the coming months. Polls suggest a majority of US voters are skeptical of the benefits of global trade and are generally favorable towards confronting China with tariffs.

The outperformance of the US economy and equity markets, energized by fiscal stimulus, emboldens the President to engage further. He has also offered economic support for the agricultural sector, a loser from Chinese retaliation and key voting bloc ahead of the November midterms. On the other hand, the President has arguably prioritized the US economy and jobs above all else. To the extent his policies create genuine damage to markets or the economy, President Trump may feel the need to dial back pressure.

China’s President Xi also has incentives and constraints for further engagement. Having shored up his leadership earlier this year, he does not face the same political pressures as President Trump.

Xi may feel he can ride out the US political cycle, prizing Chinese advancement and modernization associated with its Made in China 2025 plan with the clear goal of emerging as a genuine global superpower. Moreover, China has recently taken a number of steps to stimulate the economy, including:

  • lowering reserve requirements,
  • increasing liquidity,
  • encouraging lending to small and medium enterprises,
  • cutting taxes; and
  • allowing the yuan to weaken.

Still, China’s growth engine depends on global trade and a trade war is already disrupting the deleveraging process that China’s leadership views as key to long-term stability.

Given these dynamics, it is of course very difficult to predict how US-China tensions will all play out. At this point we think it’s reasonable to assume that tensions will heighten in the near term as there are still no signs of formal negotiations and the Trump administration is politically incentivized to impose the 10-25%/USD 200bn tariff in September.

China’s next move will be key. There is reason to believe China will retaliate but not proportionately; China’s formal response to the initiation of the latest round of US tariffs was less confrontational and specific as it was to the initial USD 50bn announcement. A less than fully proportional retaliation would create some near-term de-escalation, allowing China to appeal to the WTO and setting the stage for a return of bilateral negotiations. But clearly there is a meaningful risk of ongoing tit-for-tat escalation that undermines economic growth and risk sentiment.

The bottom line for investors

Overweight global equities despite the expectation of some trade escalation and associated market volatility over coming months. Ex-US growth is showing initial signs of stabilization, which is removing upward pressure on the US dollar. Markets should not underestimate China’s recent pivot back towards stimulus and its implications for global growth and commodities.  The combination of a stable dollar, China’s stimulus, still solid global growth and earnings should provide a cushion amid non-negligible trade risks.

Valuations for emerging market assets have become much more attractive and are already discounting significant trade escalation. As such we have begun adding EM exposure in some strategies.

In fixed income, we maintain neutral exposure to US Treasuries in case trade escalation leads to a flight to quality or a dovish re-pricing of expected Fed tightening.

And in FX, we are short the Chinese Yuan and Korean Won and long the safe haven Yen to hedge against further trade disruption.

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2020 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.